Table 3.
Author | Published time | No. of cases | Component of IMPC | Criteria of eligible patients | ER and PR | Nodal metastases | Lymphovascular invasion | |
---|---|---|---|---|---|---|---|---|
IMPC | IDC | |||||||
Chen [4] | 2008 | 100 | 100 | Mixed | Randomly selected | Lower | Lower | \ |
Yu [8] | 2010 | 72 | 144 | Pure or more than 70 % | Age, pathologic tumor and node stage, treatment methods | Higher | Higher | Higher |
Vingiani [14] | 2013 | 49 | 98 | Pure | Age, tumor size and grade | Higher | Higher | Higher |
Liu [9] | 2014 | 51 | 102 | Pure | Nodal status and age | Higher | Higher | Higher |
Shi [7] | 2014 | 188 | 1289 | mixed | Simple random sampling | Higher | Higher | Higher |
Chen [10] | 2014 | 636 | 297735 | unknown | The same study period | Higher | Higher | \ |
Yu [16] | 2015 | 267 | 267 | Mixed | Age, pathologic tumor and node stage, treatment method | Similar | Similar | Higher |
Present study | \ | 33 | 347 | Mixed | The same study period | Higher | Higher | Higher |
NO number, IMPC invasive micropapillary carcinoma, IDC invasive ductal carcinoma, ER estrogen receptor, PR progesterone receptor